Search results
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
Investor's Business Daily· 8 minutes agoOn Friday, AbbVie beat first-quarter expectations, largely on the back of its immunology franchise....
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
Proactive Investors· 8 hours agoImmunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joins Proactive's Stephen Gunnion on the International...
Decoding Immunity: The Human Immunome Project’s Strategic Blueprint To Harness AI and Immunology
SciTechDaily· 5 hours agoThe plan involves establishing global study sites and developing advanced AI tools to analyze immune...
Icahn School of Medicine at Mount Sinai Names Miriam Merad, MD, PhD, as Dean for Translational...
Newswise· 12 hours agoDr. Merad, the Mount Sinai Professor in Cancer Immunology, will also continue to serve as the...
Drugmaker AbbVie expects Humira volume erosion to worsen By Reuters
Investing.com· 3 days agoIts shares were down 2% in morning trade on Friday, after the company forecast U.S. Humira sales...
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Zacks via Yahoo Finance· 3 hours agoWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the...
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 5 days agoLilly, with a market cap of more than $700 billion, boasts a wide range of products that serve a...
FDA Update on Bird Flu Traces in Milk: What to Know About Pasteurized and Raw Milk
CNET· 13 hours agoFragments of the virus that causes bird flu, H5N1, were found in roughly one in five pasteurized...
After 'reset,' Flagship startup lands $1.8B Bristol Myers Squibb deal - Boston Business Journal
The Business Journals· 7 hours agoTorben Straight Nissen took over the reins of Repertoire Immune Medicines at the tail end of 2022,...
Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of HERCESSI™...
KTLA-TV Los Angeles· 5 hours agoAccord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced ...